| Literature DB >> 9700160 |
Abstract
In Saccharomyces cerevisiae, the unconventional myosin Myo2p is of fundamental importance in polarized growth. We explore the role of the neck region and its associated light chains in regulating Myo2p function. Surprisingly, we find that precise deletion of the six IQ sites in the neck region results in a myosin, Myo2-Delta6IQp, that can support the growth of a yeast strain at 90% the rate of a wild-type isogenic strain. We exploit this mutant in a characterization of the light chains of Myo2p. First, we demonstrate that the localization of calmodulin to sites of polarized growth largely depends on the IQ sites in the neck of Myo2p. Second, we demonstrate that a previously uncharacterized protein, Mlc1p, is a myosin light chain of Myo2p. MLC1 (YGL106w) is an essential gene that exhibits haploinsufficiency. Reduced levels of MYO2 overcome the haploinsufficiency of MLC1. The mutant MYO2-Delta6IQ is able to suppress haploinsufficiency but not deletion of MLC1. We used a modified gel overlay assay to demonstrate a direct interaction between Mlc1p and the neck of Myo2p. Overexpression of MYO2 is toxic, causing a severe decrease in growth rate. When MYO2 is overexpressed, Myo2p is fourfold less stable than in a wild-type strain. High copies of MLC1 completely overcome the growth defects and increase the stability of Myo2p. Our results suggest that Mlc1p is responsible for stabilizing this myosin by binding to the neck region.Entities:
Mesh:
Substances:
Year: 1998 PMID: 9700160 PMCID: PMC2148162 DOI: 10.1083/jcb.142.3.711
Source DB: PubMed Journal: J Cell Biol ISSN: 0021-9525 Impact factor: 10.539
Plasmids Used in This Study
| Plasmid | Parent vector | Relevant markers and construction | Reference or source | |||
|---|---|---|---|---|---|---|
| pBluescriptII KS (+) | ampr f1 origin | Stratagene | ||||
| pGEX-2T | P | Pharmacia | ||||
| pQE30 | P | Qiagen | ||||
| pRS306 |
| ( | ||||
| pRS315 |
| ( | ||||
| pRS316 |
| ( | ||||
| pGF27 | pRS304 | 2-μm origin (YEp24 fragment) inserted at AatII site | G. Zhu | |||
| pGF29 | pRS306 | 2-μm origin (YEp24 fragment) inserted at AatII site | G. Zhu | |||
| pJG28 | pSB5 | ampr trc promoter, | J. Geiser | |||
| pJP10-2B | YCp50 |
| ( | |||
| pLI831 | pBluescriptII SK (+) |
| E. Muller | |||
| myo4Δ::URA3 | pBluescriptII KS (+) |
| S. Brown | |||
| pRS23 | pBluescriptII SK (+) | 5.6-kb ClaI fragment of | This study | |||
| pRS28 | pRS27 |
| This study | |||
| pRS29 | pRS25 | 5.6-kb ClaI fragment of | This study | |||
| pRS31 | pGF29 | 5.6-kb ClaI fragment of | This study | |||
| pRS43 | pRS29 | NheI site removed | This study | |||
| pRS50 | pRS37 | 2-μm origin (YEp24 fragment) inserted at NotI site | This study | |||
| pRS72 | pRS43 | NcoI site added at codon 1 of | This study | |||
| pRS172 | pRS43 | Internal deletion of | This study | |||
| Δaa788–927) also known as | ||||||
| pRS174 | pRS306 | 5.4-kb ClaI fragment of | This study | |||
| pRS221 | pGF29 | 5.4-kb ClaI fragment of | This study | |||
| pRS276 | pBluescriptII KS (+) | 3.3-kb BamHI fragment carrying | This study | |||
| pRS286 | pRS285 |
| This study | |||
| pRS289 | pRS316 | 1.4-kb BamHI-SacI fragment of | This study | |||
| pRS290 | pGF27 | 1.4-kb BamHI-SacI fragment of | This study | |||
| pRS296 | pQE30 | ampr promoter 6XHis- | This study | |||
| pRS321 | pRS315 | 1.4-kb BamHI-SacI fragment of | This study | |||
| pSB6 | pACYC177 | kanr lysis genes of lambda | ( | |||
| pSB20 | pGEX-3X |
| ( | |||
| pSB21 | pGEX-3X |
| ( | |||
| pSB24 | pGEX-3X |
| ( | |||
| pSB25 | pGEX-3X |
| ( | |||
| pSB27 | pGEX-3X |
| ( | |||
| pTD28 | pTD17 | 2-μm origin | ( | |||
| pTD29 | YEp24 | 2-μm origin | ( |
Unless otherwise stated, all markers from the parent plasmid are present in the new construct. MYO2-Δ6IQ encodes an internal deletion in Myo2p with the mutation S787G and missing amino acids 787–927. MLC1 is identical to the Saccharomyces cerevisiae open reading frame YGL106w.
Yeast Strains
| Strain | Genotype | Reference | ||
|---|---|---|---|---|
| CRY1 |
| R. Fuller (Stanford University, CA) | ||
| JGY46 |
| ( | ||
|
| ||||
| EMY55-5D |
| E. Muller (University of | ||
| Washington, Seattle, WA) | ||||
| EMY55-6B |
| E. Muller (University of | ||
| Washington) | ||||
| MMY28 |
| ( | ||
|
| ||||
| RSY1 | EMY55-5D X EMY55-6B | This study | ||
| RSY2 |
| This study | ||
|
| ||||
|
| ||||
| RSY2-60B |
| This study | ||
|
| ||||
| RSY21 |
| This study | ||
| RSY22 |
| This study | ||
| RSY38 |
| This study | ||
|
| ||||
|
| ||||
| RSY38-9D |
| This study | ||
|
| ||||
| RSY38-16A |
| This study | ||
|
| ||||
| RSY38-16C |
| This study | ||
|
| ||||
| RSY38-17C |
| This study | ||
|
| ||||
| RSY105 |
| This study | ||
|
| ||||
|
| ||||
| RSY105-6A |
| This study | ||
|
| ||||
| RSY107 | RSY21 X RSY105-6A carrying plasmid pRS289 | This study | ||
| RSY112 |
| This study | ||
|
| ||||
|
|
GFP–CMD1 encodes a fusion protein of green fluorescent protein and calmodulin.
Figure 1The mutant MYO2-Δ6IQ allows growth. Strains carrying wild-type MYO2 (CRY1) or MYO2-Δ6IQ (RSY21) were plated on YPD medium and incubated for 3 d at 30 and 37°C (A). Log-phase cultures were diluted to 10,000 cells/μl in YPD medium, and growth was monitored over 4 h. Cell number was determined on a Coulter counter (Coulter Corporation, Hialeah, FL). (B) ▪, wild-type MYO2 strain, CRY1; •, MYO2-Δ6IQ strain, RSY21. An immunoblot of extracts made from log-phase cultures of strains CRY1 and RSY21 (C). The antibody was anti-Myo2p (Lillie and Brown, 1994).
Figure 2Comparison of the localization of Myo2p and Myo2-Δ6IQp. Cells were stained with affinity-purified anti-Myo2p antibody as described in Materials and Methods. Cells were simultaneously stained with DAPI to stain DNA. Bar, 5 μm.
Figure 3Localization of GFP–calmodulin in myo4Δ strains. Cultures of RSY38-17c (WT), RSY38-16A (myo4Δ MYO2), RSY38-9D (MYO4 MYO2-Δ6IQ), and RSY38-16C (myo4Δ MYO2-Δ6IQ) were grown to log phase. Samples were collected, mixed with equal volumes of 1% agarose dissolved in SDC, and mounted on microscope slides for image collection as described in the Materials and Methods. Bar, 5 μm.
Calmodulin Localization in Myosin Mutants
| Genotype | Polarized calmodulin (%) | |
|---|---|---|
| Wild type | 84 | |
|
| 15 | |
|
| 80 | |
|
| 4 |
Figure 4Alignment of the predicted amino acid sequence of MLC1 with three other small EF-hand proteins. Vertebrate calmodulin (Homo sapiens) amino acids 7–149, a chicken light chain (Gallus gallus, MLE1) amino acids 45–190, and Acanthamoeba myosin IC light chain (A. castellanii, MICLC) amino acids 7–149 are compared with the complete amino acid sequence of Mlc1p. Amino acid residues sharing identity between Mlc1p and at least one of the other sequences are shaded. Amino acids within potential Ca2+-binding loops are labeled with a solid line.
Figure 5MLC1 displays haploinsufficiency. Strains JGY46, RSY105, RSY107, and RSY112, each carrying the MLC1 plasmid pRS289, were streaked onto both minimal medium lacking uracil and minimal medium containing 5′-FOA (which will kill any cells that require the plasmid pRS289). The plates were incubated at 30°C for 3 d.
Figure 6mlc1Δ spores have defects in cell separation. Strains JGY46 and RSY105(pRS289) were sporulated and tetrads were dissected. After 24 h, spores were characterized into classes: (1) germinated and formed colonies, (2) germinated and did not form colonies, or (3) did not germinate. Examples of each class are shown (A). 200 spores from each strain were classified (B). Germinated spores from RSY105(pRS289) were stained with DAPI. Elongated spores with DAPI staining are shown (C). Bars, 10 μm.
Figure 7Glutathione-S-transferase (GST)–Myo2p fusion proteins.
Figure 8Gel-overlay assays show in vitro binding of Mlc1p and calmodulin to the IQ sites of Myo2p. Myo2p fusion proteins were expressed and subjected to SDS-PAGE as described in Materials and Methods. Polyacrylamide gel stained with Coomassie blue. The full-length fusion protein in each extract is marked by an arrow (A). Autoradiographs of membranes incubated with 35S-labeled 6XHis-Mlc1p (B) and 35S-labeled calmodulin (C). The gel overlay assays were performed as described in Materials and Methods. Lanes 1–6 contain extracts of IPTG-induced E. coli strain GM1 containing plasmids pGEX-2T, pSB20, pSB27, pSB21, pSB24, and pSB25, respectively. See Fig. 7 and Table I for a description of the fusion proteins.
Figure 9High copies of MLC1, but not high copies of CMD1, overcome the toxic effects of overexpressed MYO2. Plasmids used in these experiments are listed in Table I. EMY55-5D was transformed with plasmids encoding high copies of MYO2, MYO2-Δ6IQ, CMD1, or MLC1. Plates were incubated for 3 d at 30°C (A). CRY1 was transformed with pRS43, pRS172, pRS31, or pRS221, and mRNA was collected from log-phase cultures. 10 μg of polyA-containing RNA samples were analyzed as described in Materials and Methods. Blots were simultaneously hybridized with MYO2 and TRX2 32P-labeled probes (B). CRY1 was transformed with the indicated constructs to study the effects of high copies of MLC1 (pRS290) on strains with one extra copy of MYO2 (pRS43) or one extra copy of MYO2-Δ6IQ (pRS172), or overexpressing MYO2 (pRS31) or MYO2-Δ6IQ (pRS221) (C). CRY1 was transformed with the indicated constructs to study the effects of high copies of CMD1 (pTD28) on strains overexpressing MYO2 (pRS31) or MYO2-Δ6IQ (pRS221) (D). Log-phase extracts were made as described in Materials and Methods. Samples were assayed by immunoblot analysis using anti-Myo2p antibody (Lillie and Brown, 1994) to detect steady-state levels of Myo2p.
Figure 10Degradation of Myo2p. Cycloheximide was added to a final concentration of 100 μg/ml to log-phase cultures. Cultures were allowed to continue shaking, and samples were collected for immunoblot analysis as described in Materials and Methods. CRY1 containing either no plasmids (▴), plasmids pRS31 (high copies of MYO2) and pRS290 (high copies of MLC1) (▪), or pRS31 (high copies of MYO2) and pGF27 (vector alone) (•) was examined. Bands from immunoblots probed with anti-Myo2p antibody were quantified, and values were normalized for loading using a Coomassie blue–stained band that demonstrated high stability (A). The error bars represent standard deviation between two (wild type), two (with high copies of MYO2 and high copies of MLC1), or three (with high copies of MYO2) independent experiments. The immunoblots probed with anti-Myo2p antibody demonstrate Myo2p stability in CRY1 carrying either pRS31 and pRS290 (B) or pRS31 and pGF27 (C), and in CRY1 (MYO2 strain) alone (D) or in RSY21 (MYO2-Δ6IQ strain) alone (E). Numbers represent hours after cycloheximide addition.